KAZIA CEO granted 150K RSUs and 500K options

KAZIA THERAPEUTICS LTD Chief Executive Officer John E. Friend II received new equity compensation awards in the form of restricted share units and stock options tied to the company’s ADSs.

Rhea-AI Filing Summary

KAZIA THERAPEUTICS LTD Chief Executive Officer John E. Friend II received new equity compensation awards in the form of restricted share units and stock options tied to the company’s ADSs. These are grants, not open-market purchases.

The awards include 150,000 restricted share units, each representing a contingent right to receive one ADS, and 500,000 employee stock options with an exercise price of $6.78 per ADS. One-third of both the RSUs and options vest on January 8, 2027, with the remaining two-thirds vesting in equal yearly tranches on each anniversary thereafter. The options were granted for no cash consideration and expire on January 8, 2029.

Insider Trade Summary

Grant/Award: 650,000 shares

Grant/Award 2 txns

Insider Friend John E. II

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	500,000	$0.00	$0.00
Grant/Award	Restricted Share Units	150,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 500,000 contracts (Direct); Restricted Share Units — 150,000 contracts (Direct)

Footnotes (2)

1. F1. Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.
2. F2. Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer.

Key Figures

RSU grant size: 150,000 RSUs Option grant size: 500,000 options Option exercise price: $6.78 per ADS +4 more

7 metrics

RSU grant size 150,000 RSUs Board-approved award to CEO on January 8, 2026

Option grant size 500,000 options Employee stock options over ADSs to CEO

Option exercise price $6.78 per ADS Set by reference to Nasdaq closing price on January 8, 2026

Option expiration date January 8, 2029 Expiry of 500,000 employee stock options

Initial vesting date January 8, 2027 One-third of RSUs and options vest on this date

Underlying ADSs from RSUs 150,000 ADSs Each RSU equals one ADS upon vesting

Underlying ADSs from options 500,000 ADSs Shares purchasable upon option exercise at $6.78

Key Terms

Restricted Share Units, ADSs, Employee Stock Option (right to buy), exercise price, +2 more

6 terms

Restricted Share Units financial

"Represents a board-approved award of 150,000 restricted share units ("RSUs"),"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

ADSs financial

"each RSU represents a contingent right to receive one ADS of the Issuer."

Employee Stock Option (right to buy) financial

"Represents a board-approved award of 500,000 options over ADSs,"

exercise price financial

"at an exercise price of $6.78 per ADS, which was set by reference"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Remuneration Committee financial

"approved by the Remuneration Committee on January 8, 2026,"

A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.

vest financial

"One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

What equity awards did KAZIA (KZIA) CEO John E. Friend II receive?

John E. Friend II received 150,000 restricted share units and 500,000 employee stock options over KAZIA ADSs. These board-approved grants form part of his equity compensation and are not open-market share purchases.

What is the exercise price of the new KAZIA (KZIA) stock options?

The 500,000 employee stock options were granted with an exercise price of $6.78 per ADS. This price was set by reference to the closing price of KAZIA’s ADSs on Nasdaq on January 8, 2026.

How do the KAZIA (KZIA) CEO’s new RSUs and options vest?

One-third of both the 150,000 RSUs and 500,000 options vest on January 8, 2027. The remaining two-thirds vest in equal yearly tranches on each anniversary of that date, creating a multi‑year vesting schedule.

When do the new KAZIA (KZIA) CEO stock options expire?

The 500,000 employee stock options granted to the CEO expire on January 8, 2029. If not exercised by that date at the $6.78 per ADS strike price, the options will lapse and no longer be exercisable.

Did the KAZIA (KZIA) CEO pay cash for these RSU and option awards?

The filing states the 500,000 options were granted for no consideration, meaning the CEO did not pay cash to receive them. The 150,000 RSUs similarly represent a contingent right to ADSs as part of his compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Friend John E. II

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY, NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$6.78	01/08/2026		A		500,000(1)		(1)	(1)	ADSs	500,000	$0	500,000	D
Restricted Share Units	(2)	01/08/2026		A			150,000	(2)	(2)	ADSs	150,000	$0	150,000	D

Explanation of Responses:

1. Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029.

2. Represents a board-approved award of 150,000 restricted share units ("RSUs"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer.

	/s/ Jeffrey Bonacorda, Attorney-in-Fact	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)